BioCentury | Jan 27, 2014
Company News

Alvogen, Lotus Pharmaceuticals Co. Ltd. deal

Lotus will issue to Alvogen up to 151 million shares of Lotus stock valued at about $200 million. Alvogen will hold about a 67% stake in Lotus, which will use the proceeds to acquire several...
BioCentury | Jan 10, 2011
Financial News

Lotus financial update

Lotus implemented a 1-for-2 reverse stock split, effective Dec. 31, and began trading under the symbol "LTUSD." Following the split, the company has 26.7 million shares outstanding. Lotus Pharmaceuticals Inc. (OTCBB:LTUSD), Beijing, China Business: Pharmaceuticals...
BioCentury | Nov 8, 2010
Clinical News

R-bambuterol hydrochloride: Phase I started

Lotus began an open-label, Chinese Phase I trial to evaluate 2 multiple doses of R-bambuterol hydrochloride in 20 healthy volunteers. Lotus Pharmaceuticals Inc. (OTCBB:LTUS), Beijing, China Product: R-bambuterol hydrochloride Business: Inflammation Molecular target: Adrenergic receptor...
BioCentury | Nov 8, 2010
Clinical News

R-bambuterol hydrochloride: Phase I started

Lotus began an open-label, Chinese Phase I trial to evaluate 6 single doses of R-bambuterol hydrochloride in 58 healthy volunteers. Lotus Pharmaceuticals Inc. (OTCBB:LTUS), Beijing, China Product: R-bambuterol hydrochloride Business: Inflammation Molecular target: Adrenergic receptor...
BioCentury | Nov 8, 2010
Clinical News

R-bambuterol hydrochloride: Phase I started

Lotus began an open-label, crossover, Chinese Phase I trial to evaluate 3 doses of R-bambuterol hydrochloride in 12 healthy volunteers. Lotus Pharmaceuticals Inc. (OTCBB:LTUS), Beijing, China Product: R-bambuterol hydrochloride Business: Inflammation Molecular target: Adrenergic receptor...
BioCentury | Nov 8, 2010
Clinical News

R-bambuterol hydrochloride: Phase I started

Lotus began an open-label, crossover, Chinese Phase I trial to evaluate a single dose of R-bambuterol hydrochloride with and without food in 20 healthy volunteers. Lotus Pharmaceuticals Inc. (OTCBB:LTUS), Beijing, China Product: R-bambuterol hydrochloride Business:...
BioCentury | Sep 27, 2010
Company News

Lotus Pharmaceuticals management update

Lotus Pharmaceuticals Inc. (OTCBB:LTUS), Beijing, China Business: Pharmaceuticals Transitioned: Yan Zeng to CFO, she replaces Jeff Ho who resigned WIR Staff...
BioCentury | Sep 13, 2010
Company News

Lotus management update

Lotus Pharmaceuticals Inc. (OTCBB:LTUS), Beijing, China Business: Pharmaceuticals Hired: Jeff Hon as CFO, formerly manager of IPO/M&A at Westcomb Financial Group Ltd. WIR Staff...
Items per page:
1 - 8 of 8
BioCentury | Jan 27, 2014
Company News

Alvogen, Lotus Pharmaceuticals Co. Ltd. deal

Lotus will issue to Alvogen up to 151 million shares of Lotus stock valued at about $200 million. Alvogen will hold about a 67% stake in Lotus, which will use the proceeds to acquire several...
BioCentury | Jan 10, 2011
Financial News

Lotus financial update

Lotus implemented a 1-for-2 reverse stock split, effective Dec. 31, and began trading under the symbol "LTUSD." Following the split, the company has 26.7 million shares outstanding. Lotus Pharmaceuticals Inc. (OTCBB:LTUSD), Beijing, China Business: Pharmaceuticals...
BioCentury | Nov 8, 2010
Clinical News

R-bambuterol hydrochloride: Phase I started

Lotus began an open-label, Chinese Phase I trial to evaluate 2 multiple doses of R-bambuterol hydrochloride in 20 healthy volunteers. Lotus Pharmaceuticals Inc. (OTCBB:LTUS), Beijing, China Product: R-bambuterol hydrochloride Business: Inflammation Molecular target: Adrenergic receptor...
BioCentury | Nov 8, 2010
Clinical News

R-bambuterol hydrochloride: Phase I started

Lotus began an open-label, Chinese Phase I trial to evaluate 6 single doses of R-bambuterol hydrochloride in 58 healthy volunteers. Lotus Pharmaceuticals Inc. (OTCBB:LTUS), Beijing, China Product: R-bambuterol hydrochloride Business: Inflammation Molecular target: Adrenergic receptor...
BioCentury | Nov 8, 2010
Clinical News

R-bambuterol hydrochloride: Phase I started

Lotus began an open-label, crossover, Chinese Phase I trial to evaluate 3 doses of R-bambuterol hydrochloride in 12 healthy volunteers. Lotus Pharmaceuticals Inc. (OTCBB:LTUS), Beijing, China Product: R-bambuterol hydrochloride Business: Inflammation Molecular target: Adrenergic receptor...
BioCentury | Nov 8, 2010
Clinical News

R-bambuterol hydrochloride: Phase I started

Lotus began an open-label, crossover, Chinese Phase I trial to evaluate a single dose of R-bambuterol hydrochloride with and without food in 20 healthy volunteers. Lotus Pharmaceuticals Inc. (OTCBB:LTUS), Beijing, China Product: R-bambuterol hydrochloride Business:...
BioCentury | Sep 27, 2010
Company News

Lotus Pharmaceuticals management update

Lotus Pharmaceuticals Inc. (OTCBB:LTUS), Beijing, China Business: Pharmaceuticals Transitioned: Yan Zeng to CFO, she replaces Jeff Ho who resigned WIR Staff...
BioCentury | Sep 13, 2010
Company News

Lotus management update

Lotus Pharmaceuticals Inc. (OTCBB:LTUS), Beijing, China Business: Pharmaceuticals Hired: Jeff Hon as CFO, formerly manager of IPO/M&A at Westcomb Financial Group Ltd. WIR Staff...
Items per page:
1 - 8 of 8